AU2022230416A1 - Methods for the treatment of thyroid eye disease - Google Patents

Methods for the treatment of thyroid eye disease Download PDF

Info

Publication number
AU2022230416A1
AU2022230416A1 AU2022230416A AU2022230416A AU2022230416A1 AU 2022230416 A1 AU2022230416 A1 AU 2022230416A1 AU 2022230416 A AU2022230416 A AU 2022230416A AU 2022230416 A AU2022230416 A AU 2022230416A AU 2022230416 A1 AU2022230416 A1 AU 2022230416A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022230416A
Other languages
English (en)
Other versions
AU2022230416A9 (en
Inventor
Jeffrey W. Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics Ireland DAC
Original Assignee
Horizon Therapeutics Ireland DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland DAC filed Critical Horizon Therapeutics Ireland DAC
Publication of AU2022230416A1 publication Critical patent/AU2022230416A1/en
Publication of AU2022230416A9 publication Critical patent/AU2022230416A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022230416A 2021-03-03 2022-03-03 Methods for the treatment of thyroid eye disease Pending AU2022230416A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156320P 2021-03-03 2021-03-03
US63/156,320 2021-03-03
PCT/US2022/018737 WO2022187510A1 (en) 2021-03-03 2022-03-03 Methods for the treatment of thyroid eye disease

Publications (2)

Publication Number Publication Date
AU2022230416A1 true AU2022230416A1 (en) 2023-09-28
AU2022230416A9 AU2022230416A9 (en) 2024-01-25

Family

ID=83154512

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022230416A Pending AU2022230416A1 (en) 2021-03-03 2022-03-03 Methods for the treatment of thyroid eye disease

Country Status (12)

Country Link
US (1) US20240158516A1 (https=)
EP (1) EP4301410A4 (https=)
JP (1) JP2024510142A (https=)
CN (1) CN117813114A (https=)
AR (1) AR125589A1 (https=)
AU (1) AU2022230416A1 (https=)
BR (1) BR112023017797A2 (https=)
CA (1) CA3210855A1 (https=)
CO (1) CO2023012639A2 (https=)
MX (1) MX2023010278A (https=)
TW (1) TW202246339A (https=)
WO (1) WO2022187510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
US20230406942A1 (en) * 2022-06-10 2023-12-21 Horizon Therapeutics Ireland Dac Igf1r antibodies
WO2024069236A1 (en) * 2022-09-30 2024-04-04 Horizon Therapeutics Ireland Dac Methods for treating inactive or chronic thyroid eye disease
AU2024287547A1 (en) * 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2026055673A1 (en) * 2024-09-09 2026-03-12 Viridian Therapeutics, Inc. Methods for treatment of thyroid eye disease with an anti-igf-1r antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3146469B2 (ja) * 1993-09-03 2001-03-19 株式会社ニッショー 自動注射器
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2013008833A (es) * 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
MX364861B (es) * 2013-04-29 2019-05-09 Hoffmann La Roche Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares.
HRP20260151T1 (hr) * 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba

Also Published As

Publication number Publication date
BR112023017797A2 (pt) 2023-11-21
WO2022187510A1 (en) 2022-09-09
EP4301410A4 (en) 2025-03-26
CN117813114A (zh) 2024-04-02
TW202246339A (zh) 2022-12-01
CA3210855A1 (en) 2022-09-09
EP4301410A1 (en) 2024-01-10
CO2023012639A2 (es) 2023-10-09
MX2023010278A (es) 2023-11-21
AU2022230416A9 (en) 2024-01-25
AR125589A1 (es) 2023-08-02
US20240158516A1 (en) 2024-05-16
JP2024510142A (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
US12600787B2 (en) Methods for the treatment of thyroid eye disease
US12286481B2 (en) Methods for the treatment of thyroid eye disease
AU2022230416A1 (en) Methods for the treatment of thyroid eye disease
US12358993B2 (en) Methods for the treatment of thyroid eye disease
US20240301072A1 (en) Methods for the treatment of thyroid eye disease
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
US20230270851A1 (en) Methods for the treatment of idiopathic orbital inflammation and related conditions
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis

Legal Events

Date Code Title Description
SREP Specification republished